American Institute for Cancer Research (AICR)   Report issue

Foundation Phase 2
Founded: Washington D.C. United States (1982)

Organization Overview

First Clinical Trial
2019
NCT04066816
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

American Institute for Cancer Research

Active Ingredients

Drugs in Phase 2 Trials (2)

bupropion (wellbutrin) (1 trial)

naltrexone (revia) (1 trial)

Drugs in Other Trials (1)

walnut (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overweight (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3